< Back to latest news & events

News

Montenegro to become the 39th member of the EPC

September 2022

From 1 October 2022 Montenegro will become a member state of the EPO.

European patent applications (including European Regional Phase applications derived from an International PCT application) which are filed on or after this date will automatically designate Montenegro in addition to 38 other countries. Any PCT application filed on or after 1 October 2022 will automatically include Montenegro for the purpose of obtaining a European patent. Up to and including 30 September 2022, an applicant has to specifically designate Montenegro by paying the Extension fee for this state. Nationals of Montenegro and persons having their principal place of business or residence in Montenegro will also be entitled from 1 October 2022 to file international applications with the EPO as receiving Office.

This is the first expansion of the EPO since 2010 when Serbia and Albania were admitted. The EPC has grown from 7 founding states in 1977 to what will be 39 states when Montenegro joins. Bosnia and Herzegovina will be the one remaining extension state. Among the validation states there are Morocco, Tunisia, Moldova, and Cambodia. Georgia is reportedly set to become a validation state in the near future.


This update was prepared by HGF Professional Standards Officer Dr Edward Pullicino.

Latest updates

Unlocking the Soil Microbiome: Driving Agritech Innovation in the UK

The UK offers an ideal platform for harnessing the untapped potential of soil and plant microorganisms. Although much of my professional experience has focused on the human microbiome, I have …

Read article

The Antibody Series #2 | Definition via binding strength in antibody claims: when “binds strongly... but only minimally...” becomes a trap of lack of clarity

Introduction Defining an antibody by its binding strength is common practice in patent claims, but it can quickly become a pitfall under Article 84 EPC on clarity. In this second …

Read article

The Antibody Series #1 | Quality Characteristics (CQAs) in Antibody Claims: When the Test Method Can Remain Outside the Claim

Introduction Therapeutic antibodies are at the heart of innovations in biotechnology and healthcare. With increasing regulatory requirements and quality expectations, critical quality attributes (CQAs) are becoming essential in the drafting …

Read article
Event - 3rd February 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Event details

Empowered, Not Replaced: The Risks and Rewards of Using AI Tools in Patent Prosecution

With the rapid rise of AI and extreme hype around generative AI tools in the workplace, patent firms around the world have had to seriously consider to what extent they …

Read article

EU Agrees on NGT Plant Regulation: What It Means for Patents and Licensing

The European Parliament and Council have reached a provisional agreement for plants developed using New Genomic Techniques (NGTs) – below we summarise the main points and set out the requirements …

Read article

When Retail Branding Meets Politics

(Inter IKEA Systems v Algemeen Vlaams Belang (Case C‑298/23) In November 2022, the Flemish political party Vlaams Belang presented its “IKEA-PLAN – Immigratie Kan Echt Anders” (“Immigration Really Can Be Different”). …

Read article

Office Closed Dates December 2025 / January 2026

HGF Office Closed Dates December 2025 / January 2026   UK Thursday 25 and Friday 26 December 2025 CLOSED Thursday 1 January 2026* CLOSED * Friday 2 January 2026 – …

Read article